1100.2000 -14.90 (-1.34%)
NSE Sep 19, 2025 15:31 PM
Volume: 197.6K
 

1100.20
-1.34%
Prabhudas Lilladhar
We reduce earnings estimate of JUBILANT by 23%17.5%11.6% for FY21/22/23E due to weak and inconsistent performance of its Pharmaceutical segment (65% revenue and 78% EBITDA contribution in FY20) whose key contributors Radio pharma and Allergy are currently witnessing lower volumes caused by pandemic in US. Radiopharma being a hospital driven...
Number of FII/FPI investors increased from 196 to 233 in Jun 2025 qtr.
More from Jubilant Pharmova Ltd.
Recommended